Quantcast

BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know


Shutterstock photo

In the latest trading session, BioTelemetry (BEAT) closed at $67.54, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow gained 0.54%, while the tech-heavy Nasdaq added 0.76%.

Coming into today, shares of the heart monitoring device maker had lost 10.22% in the past month. In that same time, the Medical sector gained 2.18%, while the S&P 500 gained 2.53%.

Wall Street will be looking for positivity from BEAT as it approaches its nex t earnings report date. The company is expected to report EPS of $0.43, up 10.26% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $104.29 million, up 10.36% from the year-ago period.

BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.86 per share and revenue of $439.74 million. These results would represent year-over-year changes of -4.12% and +10.08%, respectively.

It is also important to note the recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 4.68% higher within the past month. BEAT is currently a Zacks Rank #1 (Strong Buy).

In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 36.62. Its industry sports an average Forward P/E of 20.23, so we one might conclude that BEAT is trading at a premium comparatively.

The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 51, which puts it in the top 20% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow BEAT in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BioTelemetry, Inc. (BEAT): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Investing , Investing Ideas , Stocks
Referenced Symbols: BEAT




More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research










Research Brokers before you trade

Want to trade FX?